Patent intelligence · US
US 7253341
Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof
Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of in…
Patent details — US 7253341
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 7, 2007
- Expiration
- Aug 2, 2027
- Applicant
- Fulcrum SP Ltd.
- Claims
- 45
- CPC classes
- A61K, A61K38/00, A61P, A61P17/02
Quick answer
US 7253341 (Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof) is held by Fulcrum SP Ltd.. Status: granted. Granted Aug 7, 2007. Expires Aug 2, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Fulcrum SP Ltd.
- Grant date
- Expiration
- Claims
- 45
- CPC classes
- A61K, A61K38/00, A61P, A61P17/02, A61P37/06
More from Fulcrum SP Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12109198
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
granted -
US 11819554
Compositions and methods for modulating FMR1 expression
granted -
US 11590111
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
granted -
US 11479770
Use of p38 inhibitors to reduce expression of DUX4
granted -
US 11291659
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted -
US 10973805
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
granted -
US 10537560
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted -
US 10342786
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted
Frequently asked questions
What is US patent 7253341?
US 7253341 (Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof) is held by Fulcrum SP Ltd.. Status: granted. Granted Aug 7, 2007. Expires Aug 2, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7253341?
Fulcrum SP Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 7253341 expire?
Our index shows an expiration date of Aug 2, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.